Drug intelligence / Profile preview

camrelizumab + cyclophosphamide + epirubicin + nab-paclitaxel

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This combination involves **camrelizumab**, an anti-PD-1 monoclonal antibody used in immunotherapy, **cyclophosphamide** and **epirubicin**, which are chemotherapeutic agents, and **nab-paclitaxel**, a solvent-free formulation of paclitaxel. The combination is used in the treatment of triple-negative breast cancer (TNBC), enhancing the efficacy of chemotherapy by targeting the PD-1/PD-L1 pathway.

Targets

TOP2A (DNA topoisomerase II)DNAPDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on camrelizumab + cyclophosphamide + epirubicin + nab-paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on camrelizumab + cyclophosphamide + epirubicin + nab-paclitaxel.

Explore the full profile